ABBVIE INC. (NYSE:ABBV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective December13, 2018, Michael E.Severino, M.D., 52, has been appointed Vice Chairman and President, Laura J. Schumacher, 55, has been appointed Vice Chairman, External Affairs and Chief Legal Officer, and Carlos Alban, 55, has been appointed Vice Chairman, Chief Commercial Officer. A copy of a press release announcing these appointments is attached hereto as Exhibit99.1 and is incorporated herein by reference.
Dr.Severino has served as AbbVie’s Executive Vice President, Research and Development and Chief Scientific Officer since he joined AbbVie in 2014. He previously served at AmgenInc. as Senior Vice President, Global Development and Corporate Chief Medical Officer from 2012 to 2014.
Ms.Schumacher served as AbbVie’s Executive Vice President, External Affairs, General Counsel and Corporate Secretary, responsible for AbbVie’s externally-facing functions of Health Economics Outcomes Research, Government Affairs, Corporate Responsibility, Brand and Communications since 2015. She served as AbbVie’s Executive Vice President, Business Development, External Affairs and General Counsel from 2012 to 2015. Ms.Schumacher joined Abbott Laboratories (“Abbott”), AbbVie’s former parent company, in 1990. Ms.Schumacher also serves on the board of General Dynamics Corporation.
Mr.Alban has served as AbbVie’s Executive Vice President, Commercial Operations since 2012. Mr.Alban joined Abbott in 1986.
Item 9.01 Financial Statements and Exhibits
Press Release dated December17, 2018.
AbbVie Inc. Exhibit
EX-99.1 2 a18-41691_1ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE AbbVie Announces Executive Leadership Changes NORTH CHICAGO,…
To view the full exhibit click
About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.